Pulmonary Drug Delivery Systems Market size was over USD 60.56 billion in 2024 and is set to reach USD 140.32 billion by the end of 2037, growing at around 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of pulmonary drug delivery systems is assessed at USD 63.81 billion.The growth of the market can be attributed to the surge in cases of asthma worldwide, coupled with increasing instances of pulmonary disorders, and growing funding from government and private organizations for better therapy management across the globe. People are now becoming more aware of these diseases and disorders, which is further expected to fuel the market over the forecast period. According to the World Health Organization, an estimated 262 million people suffered from asthma around the world in 2019 and it caused 455 000 deaths.
Global pulmonary drug delivery systems market trends such as, technological advancements in the pharmaceutical industry, increasing consumption of tobacco and smoking, backed by exposure to air pollution, along with development in drug delivery systems owing to growing health care spending are anticipated to fuel market growth during the forecast period. For instance, in February 2022, AptarGroup, Inc. launched HeroTracker Sense, a smart connected respiratory health device, that transforms a standard metered dose inhaler (pMDI) into a digital respiratory health tool. Hence, all these factors are anticipated to boost the market’s growth over the forecast period.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.8% |
|
Base Year Market Size (2024) |
USD 60.56 billion |
|
Forecast Year Market Size (2037) |
USD 140.32 billion |
|
Regional Scope |
|
Application (Asthma, Cystic Fibrosis, COPD, Allergic Rhinitis)
The global pulmonary drug delivery systems market is segmented and analyzed for demand and supply by application into asthma, cystic fibrosis, COPD, allergic rhinitis, and others. Out of these segments, the COPD segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the higher prevalence and severity of this disease, backed by the fact that the treatment for COPD is subsidized by government policies and non-governmental organizations that are increasingly providing COPD treatment worldwide. Chronic obstructive pulmonary disease (COPD) can be life-threatening that requires immediate medical attention. For instance, COPD prevalence worldwide was 10% in 2019, accounting for 390 million cases among people over 40 years. Therefore, these factors are anticipated to drive segment growth during the forecast period.
Product (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers, Accessories)
The global pulmonary drug delivery systems market is also segmented and analyzed for demand and supply by product into metered dose inhalers, dry powder inhalers, nebulizers, and accessories. Amongst these segments, the nebulizers segment is expected to garner a significant share. Nebulizers are highly used for the treatment of asthma and other respiratory diseases. Nebulizers come in two types, ultrasonic and jet nebulizers. Jet nebulizers can compress air and oxygen passing by narrow orifice. Additionally, nebulizers are the traditional method to cure respiratory diseases, hence, people are more inclined to use nebulizers over other methods. Furthermore, high export and import volumes of nebulizers across the globe are also expected to propel the growth of the segment over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By Distribution Channel |
|
The North America pulmonary drug delivery systems market is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the increasing prevalence of lung diseases such as COPD, chronic bronchitis, and asthma in the region owing to heavy consumption of tobacco, cigarettes, exposure to air pollutants, genetic factors, and others. It was observed that in 2018, there were 8.9 million adults in the United States who experienced chronic bronchitis, or 3.5% of those over the age of 18 years. A surge in the air pollution and exposure to air pollutants in the region that results in a higher number of respiratory diseases in the population is estimated to expand the market’s size during the forecast period. As of 2021, nearly 65 million tons of pollution were estimated to be mixed in the atmosphere in the USA. Additionally, more than 62% of the Americans were noticed to be living in high air polluted areas at unhealthy levels making people sick. Furthermore, increasing healthcare spending, rising disposable income, the presence of major key players, changes in lifestyle, and growing demand for COPD therapeutics are factors anticipated to fuel the pulmonary drug delivery systems market growth in the region during the forecast period.
Novartis AG reported that a new treatment option for Japanese patients was approved by the Ministry of Health, Labour, and Welfare (MHLW). NSCLC with METex14 mutations can be treated with TabrectaTM (capmatinib, formerly INC280), an oral MET inhibitor. Tabrecta became the first-line approved treatment type for patients living with lung cancer advanced non-small cell lung cancer.
Lupin Limited launched Adhero, a smart inhaler tracking device designed to support the treatment of COPD patients and respiratory diseases. Adhero also provide therapy and assistance to the people living with chronic respiratory diseases. Additionally, Adhero is getting fame owing to the fact that inhalers are most convenient treatment methods for chronic respiratory diseases.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?